Date: 2016-08-31
Type of information: Distribution agreement
Compound: SelectMDx™ for Prostate Cancer
Company: MDxHealth (Belgium) Teva Pharmaceuticals (Israel)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: distribution
Action mechanism: biomarker/diagnostic test. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs. The novel biomarkers that make up SelectMDx were discovered by Prof. Dr. Jack Schalken, original developer of the PCA3 assay, and his team at the Department of Urology at Radboud University Medical Center in the Netherlands. The SelectMDx test was designed to address an unmet need in the stratification of patients at risk for potentially lethal high-grade prostate cancer compared to those with low-grade cancer.
Disease: prostate cancer
Details: * On August 31, 2016, MDxHealth announced that it has signed a distribution agreement with Teva Pharmaceuticals to offer its SelectMDx™ for Prostate Cancer test to Teva's urology customers throughout Israel. Under the terms of the three-year agreement, Teva Pharmaceuticals will be the exclusive distributor of the SelectMDx™ for Prostate Cancer test in Israel. Samples will be sent to MDxHealth's state-of-the-art clinical diagnostic laboratory in Nijmegen, The Netherlands for analysis. Teva will reimburse MDxHealth for all the testing services.
Financial terms:
Latest news:
